Search
  • rpierce2019

Leveraging Synthetic Biology to Create Better Treatments For Lynch Syndrome and FAP

Updated: May 18

Engineered Nissle bacteria has been previously tested pre-clinically and in Phase 2 clinical trails. It was well tolerated and elucidated desired biologic effects. This is why we are engineering Nissle bacteria for human clinical evaluation in a variety of rare diseases.

#engineeredbacteria #geneswitches #platformtechnology #raredisease #Nissle1917 #sanaRx #Cancer #geneticcancers #Colorectalcancer #FAP #Lynchsyndrome

In Clinical Trails Engineered Nissle Was Shown to Well Tolerated and Clear The Gut

51 views
 

Address

Pagliuca Harvard Life Lab

127 Western Ave

Allston MA 02139

USA

Contact

6174478299

©2019 by FEP Capital Advisors, LLC.